A detailed history of Dcf Advisers, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Dcf Advisers, LLC holds 1,000 shares of BIIB stock, worth $173,790. This represents 0.12% of its overall portfolio holdings.

Number of Shares
1,000
Holding current value
$173,790
% of portfolio
0.12%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$190.52 - $236.72 $190,520 - $236,720
1,000 New
1,000 $231,000
Q1 2023

May 15, 2023

BUY
$256.56 - $292.34 $1.26 Million - $1.43 Million
4,900 New
4,900 $1.36 Million
Q4 2021

Feb 10, 2022

SELL
$223.92 - $287.77 $447,840 - $575,540
-2,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$282.99 - $369.05 $282,990 - $369,050
1,000 Added 100.0%
2,000 $566,000
Q2 2021

Aug 13, 2021

BUY
$259.0 - $414.71 $259,000 - $414,710
1,000 New
1,000 $346,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Dcf Advisers, LLC Portfolio

Follow Dcf Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dcf Advisers, LLC with notifications on news.